Is VRML a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

394 people get VRML articles and Market Currents by email alert.

Get email alerts on VRML »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Is Vermillion's OVA1 Test Finally Gaining Traction?
Edward Dostillio • Thu, Mar 29, 2012 • 2 Comments
Vermillion Hijacked
George Bessenyei • Mon, Jan 2, 2012 • 6 Comments
Vermillion: Turning The Page Over
George Bessenyei • Tue, Dec 20, 2011 • 13 Comments
Novel Diagnostic Tests Utilizing Biomarkers Working Well for Vermillion
Rod Raynovich • Tue, Nov 30, 2010 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Complete Chris Hansen And Valiant Capital Portfolio Update
Profit Fan • Fri, May 17
Emerging Biomarker Companies Redux: Positioned For Growth
Rod Raynovich • Wed, May 15 • 5 Comments
Valiant Capital's Worst Performing Stock Picks YTD
Profit Fan • Mon, May 13 • 3 Comments
Detecting Investment Potential In Medical Diagnostics Companies
Chemistfrog • Tue, May 7 • 5 Comments
The Anti-Buffett Portfolio: Chris Hansen And Valiant Capital's Year-End Holdings
Profit Fan • Mon, Mar 11 • 2 Comments
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
Update On Emerging Biomarker Diagnostics: BG Medicine, Response Genetics, Vermillion
Rod Raynovich • Thu, Nov 15, 2012
2 Solid Stocks And 1 Gamble For A Successful Holiday Season
Ian Agar • Mon, Nov 12, 2012 • 10 Comments
Emerging Biomarker Diagnostics: BGMedicine And Vermillion
Rod Raynovich • Wed, Apr 4, 2012 • 4 Comments
Valiant Capital Management's Q4 Stock Picks
Insider Monkey • Fri, Feb 10, 2012 • 1 Comment
Mid-Sized Canadian Oil and Gas Companies Show How Hedging Pays Off
Evaluate Energy • Thu, Jul 21, 2011
2009's Top Sector for Venture Investment: Biotech
The Burrill Report • Mon, Jan 25, 2010 • 1 Comment
Update on SAC Capital's Dendreon, Vermillion Holdings
Market Folly • Tue, Jan 19, 2010 • 2 Comments
Biotech Exits 2009 with a Whimper
The Burrill Report • Tue, Jan 5, 2010

Vermillion Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 15
Vermillion Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 20
Vermillion's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 12, 2012
Vermillion Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 14, 2012

Vermillion's OVA1 Receives New Statement by Society of Gynecologic Oncology

PR Newswire (Jun 11, 2013)
After Hours: Cisco, Tesla shares jump after hours

at MarketWatch.com (May 15, 2013)
Vermillion Reports First Quarter 2013 Results

PR Newswire (May 15, 2013)
Vermillion Announces Closing of Equity Financing

PR Newswire (May 14, 2013)
Vermillion Announces Equity Financing

PR Newswire (May 9, 2013)
Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment

PR Newswire (May 8, 2013)
Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013

PR Newswire (May 1, 2013)
U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care

PR Newswire (Apr 17, 2013)
Vermillion Appoints Bruce A. Huebner to Chairman of the Board

PR Newswire (Mar 19, 2013)
Vermillion Appoints Thomas McLain as President and Chief Executive Officer

PR Newswire (Mar 13, 2013)
Vermillion Reports Fourth Quarter and Full Year 2012 Results

PR Newswire (Feb 20, 2013)
Vermillion to Report Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013

PR Newswire (Feb 19, 2013)
Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013

PR Newswire (Feb 19, 2013)
Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET

PR Newswire (Feb 8, 2013)
Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillion's Ovarian Cancer Test

PR Newswire (Nov 28, 2012)
Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer

PR Newswire (Nov 27, 2012)
Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice

PR Newswire (Nov 19, 2012)
Vermillion Reports Third Quarter 2012 Results

PR Newswire (Nov 12, 2012)
Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET

PR Newswire (Oct 29, 2012)
Vermillion to Present at the 2012 Gateway Conference on September 6

PR Newswire (Aug 28, 2012)

VRML vs. ETF Alternatives

Company Description

Currently, there's no company description for VRML.

Sector: Healthcare

Industry: Diagnostic Substances

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 4, 12:45 PM Midday top 10 gainers: ET +53%. NURO +47%. INFI +20%. GIII +18%. OIBR +18%. IFMI +12%. MHGC +13%. WPCS +13%. BEAT +12%. AMPE +12%. Midday top 10 Losers: FBN -19%. RIGL -18%. LPHI -13%. PSTI -14%. GIG -10%. BTX -10%. OSH -10%. VRML -10%. ENTA -9%. ZLC -10%. Comment!
Wednesday, May 15, 4:47 PM More on Vermillion (VRML): Q1 beats on the top line with higher OVA1 product sales, but misses on its EPS. Net losses increased as one-time items, including costs related to the delayed 2012 annual shareholder meeting held in March, a proxy contest and CEO transition all weighed on margins. Shares -18.7% AH. Comment! [Earnings, On the Move, Healthcare]
Wednesday, May 15, 4:24 PM Vermillion (VRML): Q1 EPS of -$0.17 misses by $0.02. Revenue of $328K beats by $28.K. Shares -15.4% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Tuesday, May 14, 2:00 PM Vermillion (VRML -2.3%) reverses earlier gains to trade lower today, after saying it's closed its 8M share private placement, with net proceeds of $11.8M after expenses. The company also issued warrants for 12.5M shares of stock at $1.46 per share, which could give VRML an additional $18.3M in proceeds, bringing the total gross proceeds to $31.5M. 1 Comment [Healthcare, On the Move]
Friday, May 10, 12:52 PM Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%. Comment! [On the Move]
Thursday, May 9, 2:55 PM Vermillion (VRML +39%) soars today after reporting earlier that Oracle Investment Management and other investors will make an initial investment of $13.2M by purchasing 8M shares of the company's stock. VRML will also issue 12.5M warrants with a strike price of $1.46 for $18.3M in proceeds, bringing the total gross investment to $31.5M. Proceeds will be used to increase test sales and improve reimbursement for OVA1, as well as to expand into new markets and advance next-generation ovarian cancer diagnostic tests. Comment! [Healthcare, On the Move]
Thursday, May 9, 12:46 PM Midday top 10 gainers: TRMD +94%. OPTT +42%. VRML +32%. AFFY +28%. TSLA +27%. XOMA +26%. GMCR +25%. CTRP +24%. OWW +23%. CHYR +19%.
Midday top 10 losers: LPSN -34%. PZZI -33%. RAX -26%. KEM -25%. NSYS -23%. MNOV -22%. WG -20%. GV -18%. ORBT -16%. OFIX -16%. Comment! [On the Move]
Wednesday, April 17, 9:21 AM Vermillion (VRML) +29.4% premarket after the developer of diagnostic tests signs a cooperative research and development agreement with the U.S. Army. A two-phase study will investigate the cost-benefit profile of OVA1 testing as a presurgical standard of care in women with pelvic masses, and assess OVA1 clinical utility in a managed care setting. Comment! [Healthcare, On the Move]
Wednesday, April 17, 9:12 AM Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%. 1 Comment [On the Move]
Wednesday, February 20, 7:32 PM Vermillion (VRML): Q4 EPS of -$0.09 beats by $0.03. Revenue of $1.14M (+32% Y/Y) beats by $0.2M. Shares -1.5% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Thursday, November 29, 2012, 12:45 PM Midday top 10 gainers: HGSH +48%. ACUR +46%. PBM +42%. BLOX +36%. OCZ +24%. THQI +23%. AXR +22%. CARV +21%. TELK +20%. OBCI +16%.
Midday top 10 Losers: LQDT -17%. VRML -13%. ATEA -12%. LZB -11%. HITK -10%. KSS -9%. LAS -9%. BKS -9%. ABCD -8%. PIP -7%. Comment! [On the Move]
Wednesday, November 28, 2012, 12:45 PM Midday top 10 gainers: VRML +34%. SHS +32%. GMCR +24%. SPMD +18%. TROV +17%. GPOR +16%. IDIX +15%. TSL +15%. KCG +14%. AXR +12%.
Midday top 10 Losers: UTI -24%. CLUB -21%. CFNB -16%. GENE -15%. TFM -14%. CBAK -13%. SBGI -12%. DWCH -13%. NFEC -11%. CAP -9%. 2 Comments [On the Move]
Monday, November 12, 2012, 4:57 PM More on Vermillion (VRML): Q3 beats bottom line consensus on lower-than-anticipated losses. Revenue was flat on a Y/Y basis, while earnings got a big boost from better cost controls. Operating expenses decreased by nearly half as compared to the prior year period, driven by lower clinical trial costs, fewer legal expenses and ongoing cost containment initiatives. Shares +7.5% AH. Comment! [Healthcare, Earnings, On the Move]
Monday, November 12, 2012, 4:31 PM Vermillion (VRML): Q3 EPS of -$0.13 beats by $0.08. Revenue of $319K in-line. (PR) Comment! [Earnings, Healthcare]
Tuesday, October 16, 2012, 12:45 PM Midday top 10 gainers: NOOF +54%. DSTI +37%. INVE +31%. BCOM +17%. PAMT +16%. PRXI +16%. TRT +16.%. APPY +13%. ARL +12%. RLGT +11%. Top 10 Losers: AONE -75%. RATE -24%. OSG -22%. KFS -19%. ISIS -18%. VRML -18%. CLWR -15%. OCZ -11%. CMRE -11%. VIMC -10%. 1 Comment [On the Move]
Monday, July 30, 2012, 9:14 AM Vermillion (VRML) +14.4% premarket after announcing "positive" top-line results from its OVA1 ovarian cancer diagnostic from a clinical study. VRML says OVA1 represents "a new class of software-based diagnostics"; it is the first protein-based, in vitro diagnostic multivariate index assay cleared by the FDA. Comment! [Healthcare, On the Move]

freefdawatchlist
http://bit.ly/IWuHwi After hours big gainer: OSUR, COGO, SINA, VRML, OIBR, GM, IRE Loser: CLNT, GCOM, GLPW, TRNS, PMFG, JCP, WPC
5/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
High-Flying Stock Setups for Today with entries: $VRML $SONE $PCYC $NYT $AVNW http://bit.ly/ipi8SG
6/7/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Duediligence101
VRML Great science, huge open ended opportunity. CEO has made it a bad stock over the past year. OVA1 ramp and PAD approval are key.
3/30/11
Reply (1)

• !Report Abuse
View all 1 replies
sundate36: Would you buy VRML at 1.40? 2013 seems to be looking good for them. Thanks!
12/21/12
• !Report Abuse
Add a reply...

140 characters

Duediligence101
VRML - Great science - CEO has to be removed. Amazing long term risk/reward.
3/30/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Duediligence101
VRML Great science, huge open ended opportunity. CEO has made it a bad stock over the past year. OVA1 ramp and PAD approval are key.
3/30/11
Reply (1)

• !Report Abuse
View all 1 replies
sundate36: Would you buy VRML at 1.40? 2013 seems to be looking good for them. Thanks!
12/21/12
• !Report Abuse
Add a reply...

140 characters

VRML Vermillion, Inc.

VRML

Vermillion, Inc.